Evidence‑Based Recommendations for Percutaneous Coronary Intervention (PCI)
1. Indications & Timing
- Primary PCI should be performed within 12 hours of symptom onset for STEM‑MI patients (Class I, Level A). 3
- Door‑to‑balloon time ≤ 90 minutes is required for hospitals with on‑site PCI capability (Class I, Level B). 3
- Door‑to‑balloon time ≤ 120 minutes is acceptable for patients transferred from non‑PCI hospitals (Class I, Level B). 3
- Patients presenting with severe heart failure or cardiogenic shock should receive primary PCI regardless of elapsed time (Class I, Level B). 3
- PCI is indicated when fibrinolytic therapy is contraindicated and symptoms are < 12 h (Class I, Level B). 3
- For ongoing ischemia 12–24 h after symptom onset, PCI is reasonable (Class IIA, Level B). 3
- After successful fibrinolysis in hemodynamically stable patients, coronary angiography should be performed 3–24 h later (Class IIA, Level A). 3
- If fibrinolysis fails or there is a large myocardium at risk, immediate angiography is reasonable (Class IIA, Level B). 3
- In chronic total occlusions, PCI is reasonable when angina is refractory to optimal medical therapy or when large ischemic territories are documented (Class IIA, Level B). 1
- Symptom improvement (angina, exertional dyspnea, fatigue) despite optimal medical therapy is the only benefit of PCI demonstrated in randomized trials and should be the primary indication (Class I, Level B). 1
2. Pre‑Procedural Planning
- All PCI procedures require thorough pre‑procedural planning with detailed angiographic review; ad‑hoc PCI should be avoided to allow risk‑benefit assessment, patient counseling, and strategy development (Class I, Level B). 1
- Dual coronary angiography using two catheters and pressure‑monitoring systems improves technical success and reduces complications (Class I, Level B). 1
- Key angiographic characteristics to assess before CTO‑PCI: proximal cap morphology, occlusion length/course/composition, distal vessel quality, and collateral circulation (Class I, Level B). 1
- An office‑based risk/benefit discussion with the patient before CTO‑PCI is strongly encouraged (Class I, Level B). 1
- Patients must be counseled on the necessity and risks of dual antiplatelet therapy (DAPT) before stent implantation; alternative strategies should be considered if adherence is uncertain (Class I, Level B). 6
3. Anticoagulation During PCI
| Anticoagulant | Dosing Strategy | Target ACT / Monitoring | Recommendation |
|---|---|---|---|
| Unfractionated Heparin + GP IIb/IIIa inhibitor | 50–70 U/kg bolus | 200–250 s | Class I, Level B |
| Unfractionated Heparin without GP IIb/IIIa inhibitor | 70–100 U/kg bolus | 250–300 s | Class I, Level B |
| Eptifibatide or Tirofiban (with UFH) | – | < 300 s | Class I, Level B |
| Post‑procedural heparin infusion during GP IIb/IIIa therapy | – | – | Not recommended (Class III, Level B) |
| Enoxaparin – PCI ≤ 8 h after last SC dose | No additional anticoagulant | – | Class I, Level B |
| Enoxaparin – PCI 8–12 h after last SC dose | 0.3 mg/kg IV immediately before PCI | – | Class I, Level B |
| ACT guidance in patients on LMWH | – | ACT should not be used | Class I, Level B |
| Sheath removal timing after UFH/LMWH | 4 h after last IV dose or 6–8 h after last SC dose | – | Class I, Level B |
All recommendations above are from the American College of Cardiology/American Heart Association (ACC/AHA) guideline (Class I–III, Levels A–B).
4. Device‑Specific Considerations
- Embolic protection devices should be employed during saphenous vein graft PCI whenever technically feasible (Class I, Level B). 6
- Elective insertion of a hemodynamic support device may be reasonable in carefully selected high‑risk PCI patients (Class IIb, Level C). 6
- Stent optimization, including routine use of intravascular imaging, is recommended in CTO‑PCI to improve outcomes (Class I, Level B). 1
5. Dual Antiplatelet Therapy (DAPT)
Loading doses for acute coronary syndrome (ACS) patients:
- Clopidogrel 600 mg (Level B)
- Prasugrel 60 mg (Level B)
- Ticagrelor 180 mg (Level B)
- (All citations: 6)
Clopidogrel loading after fibrinolysis: 300 mg within 24 h; 600 mg if > 24 h (Level C) 6
Maintenance aspirin: 81 mg daily (preferred over higher doses, Level B) 6
P2Y12 inhibitor duration:
- ACS patients receiving any stent (BMS or DES): ≥ 12 months (Level B) 6
- Non‑ACS patients with DES: ≥ 12 months of clopidogrel 75 mg daily if not at high bleeding risk (Level B) 6
- Non‑ACS patients with BMS: Minimum 1 month (up to 12 months); at least 2 weeks if bleeding risk is high (Level B) 6
- If bleeding risk outweighs benefit, earlier discontinuation (< 12 months) is reasonable (Class IIA, Level C). 6
6. Post‑Procedural Management
- Hemostasis monitoring: A post‑PCI hematocrit drop > 5–6 % signals bleeding and warrants evaluation (Class I, Level B).** 7
- Retroperitoneal hematoma: Look for hypotension, suprapubic/back pain; CT confirms diagnosis; > 80 % managed conservatively with transfusion (Class I, Level B).** 7
- Hospital discharge: Most patients can be safely discharged the day after an uncomplicated elective PCI (Class I, Level B).** 7
- Discharge checklist: Monitor for recurrent ischemia, ensure hemostasis at the access site, assess for contrast‑induced renal injury, evaluate vascular closure device performance, and initiate secondary atherosclerosis‑prevention measures (Class I, Level B).** 7
7. Procedural Pitfalls to Avoid
- Do not perform ad‑hoc CTO‑PCI; pre‑planning reduces contrast and radiation exposure and allows thorough patient discussion (Class I, Level B). 1
- Avoid PCI of a non‑infarct artery during primary PCI in hemodynamically stable patients (Class III, Level B). 3
- Do not attempt PCI of a totally occluded infarct artery > 24 h after STEMI in stable, asymptomatic patients without severe ischemia (Class III, No Benefit). 5